PFE
Pfizer Inc
Pfizer Inc historical holders
total: 21
Cullen Value Fund Pfizer Inc transactions over time
- Total transactions:
- 8
- New positions:
- 2
- Sold out:
- 2
- Added:
- 1
- Reduced:
- 3
- Held since:
- 2025 Q4
- Held for:
- 2 quarters
- Latest activity:
- 2026 Q2
Jim Cullen has been an institutional investor in Pfizer Inc (PFE) since 2019 Q3. According to 2026 Q2 report, Jim Cullen doesn't hold any shares. The fund/company first acquired PFE in 2019 Q3, initially purchasing 29,550 shares. Jim Cullen later completely sold out the position and reinvested in PFE again in 2025 Q4. Since the initial investment, Cullen Value Fund has made 7 more transactions in this position.
When did Jim Cullen exit their PFE position?
Jim Cullen no longer holds Pfizer Inc (PFE). They sold off their entire position in 2026 Q2, closing out an investment that began in 2019 Q3.
When did Jim Cullen first invest in PFE?
Jim Cullen first invested in Pfizer Inc (PFE) in 2019 Q3 at the reported quarter-end price of $35.93 per share, acquiring 29,550 shares in their initial purchase.
What is Jim Cullen's average cost basis for PFE?
Based on historical transaction data, Jim Cullen's estimated cost basis for Pfizer Inc (PFE) is approximately $24.90 per share. This represents their average reported price* across all buy transactions.
Has Jim Cullen reinvested in PFE after selling?
Yes, Jim Cullen has shown renewed interest in Pfizer Inc (PFE). After completely selling their position, they reinitiated an investment in 2025 Q4, demonstrating continued conviction in this ticker.
Estimated cost basis*
- Weighted AVG buy price:
- $24.90
- Weighted AVG sell price:
- $28.08
PFE transactions history by Cullen Value Fund
8 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
0.00%
|
0
|
$28.08
|
|
-100% (-21,860)
|
-2.16%
|
|
2025 Q4
|
1.97%
|
21,860
|
$24.90
|
$544,314
|
new
|
+1.97%
|
|
2025 Q2
|
0.00%
|
0
|
$25.34
|
|
-100% (-14,674)
|
-1.61%
|
|
2023 Q1
|
2.71%
|
14,674
|
$40.80
|
$598,699
|
-26.99% (-5,424)
|
-0.93%
|
|
2022 Q3
|
4.23%
|
20,098
|
$43.76
|
$879,488
|
-8.94% (-1,974)
|
-0.37%
|
|
2020 Q4
|
3.28%
|
$36.81
|
+4.88% (+1,027)
|
|||
|
2019 Q4
|
2.75%
|
$39.18
|
-28.78% (-8,505)
|
|||
|
2019 Q3
|
2.73%
|
$35.93
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.